Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) sold under brand names such as Voltaren and Cataflam, and available as an oral tablet, an extended release capsule, and a topical gel. Employees who take it for arthritis, back pain, or other inflammatory conditions sometimes ask whether it can turn a routine workplace urine screen into a false positive. The honest answer is nuanced: older published literature on NSAIDs as a class reports occasional cross reactivity on some cannabinoid (THC) and barbiturate immunoassays, but the evidence specific to diclofenac is thin, and any screening result that looks unusual is resolved by laboratory confirmation and a medical review officer (MRO), not by guesswork at the collection site.
Screening immunoassay versus confirmation testing
A workplace urine drug test almost always starts with an immunoassay, the kind of test used in a point of care cup or dip card. Immunoassays work by looking for antibody binding to a target drug class. They are fast and inexpensive, but they are a screen, not a final answer. An antibody built to recognize one molecule can sometimes also bind, weakly, to a chemically similar molecule from an unrelated drug. That is called cross reactivity, and it is the mechanism behind almost every false positive discussion involving common medications.
When a screen comes back nonnegative, a certified laboratory runs a confirmation test, typically gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS). These methods identify the specific molecule and its mass, not just an antibody reaction, so they do not confuse diclofenac or any other NSAID with an actual cannabinoid or barbiturate metabolite. A review of commonly prescribed medications and their potential to trigger false positive immunoassay screens, published in the American Journal of Health System Pharmacy, documents this pattern across many drug classes: certain NSAIDs have been reported to cross react with some screening assays for cannabinoids or barbiturates, while confirmation testing reliably separates the true result from the screening artifact.
It also helps to be specific about which drug classes diclofenac is not part of. Diclofenac is not an opioid, not an amphetamine or methamphetamine, not a benzodiazepine, not cocaine, and not phencyclidine (PCP). A standard workplace panel, whether it is a five panel, seven panel, or ten panel cup, screens for those classes plus cannabinoids and, on some panels, barbiturates. Diclofenac has no pharmacological relationship to any of those drug classes. The only documented interference question in the literature involves antibody cross reactivity on certain cannabinoid or barbiturate immunoassay chemistries, which is a laboratory chemistry issue rather than evidence that diclofenac is itself a controlled substance or behaves like one in the body.
What the literature actually says about NSAIDs
The NSAID and false positive question is older than diclofenac's own prescribing history. Reports from past decades flagged ibuprofen and naproxen, in particular, as occasional sources of nonnegative immunoassay results on some cannabinoid and barbiturate screens, usually tied to specific assay chemistries and higher ingested doses. A widely cited practical guide to urine drug screening for clinicians, published in Mayo Clinic Proceedings, lays out this same pattern: a small number of NSAIDs have been associated with cross reactivity on older assay formulations, while newer, more antibody specific immunoassays are far less prone to the problem.
Diclofenac itself is not one of the NSAIDs with a substantial published record of causing cannabinoid or barbiturate immunoassay cross reactivity. There is limited to no published evidence tying diclofenac specifically to a false positive THC or barbiturate screen. That does not mean a false positive is impossible on every assay ever manufactured, since assay chemistry varies by manufacturer and by lot, but it does mean employers and employees should not treat diclofenac use as an expected or routine cause of a nonnegative screen. If a diclofenac prescription did produce an unusual screening result, the correct next step is the same as for any other medication: let laboratory confirmation and the MRO review settle the question, not an assumption about the drug.
| Step | What it checks | What it tells you |
|---|---|---|
| Point of care screen (cup or dip card) | Antibody binding to a drug class | Nonnegative or negative, not drug specific, subject to cross reactivity |
| Laboratory confirmation (GC/MS or LC/MS) | Exact molecule and concentration | Confirms or rules out the specific substance; resolves cross reactivity |
| MRO review | Prescription documentation, medical explanation | Final determination of whether a confirmed positive is verified positive or legitimate medical use |
Topical gel versus oral diclofenac
Diclofenac is sold both as an oral tablet or capsule and as a topical gel applied directly to the skin over a joint or muscle. The two forms have very different systemic absorption. Oral diclofenac is absorbed through the gastrointestinal tract and reaches measurable blood levels, which is reflected in the prescribing information for oral diclofenac sodium delayed release tablets on DailyMed. Topical diclofenac gel is designed for localized delivery with substantially lower systemic absorption than the oral product, as described in the topical gel labeling also indexed on DailyMed. Lower systemic exposure from the topical form means less drug circulating in blood and excreted in urine overall, though neither form has a meaningful published connection to cannabinoid or barbiturate immunoassay cross reactivity. Either way, the form a patient uses is a detail worth including with any prescription documentation given to an MRO, since it helps explain dosing context if a question ever comes up.
What federally regulated testing actually requires
Employers who test under United States Department of Transportation rules follow 49 CFR Part 40, which sets the drug panel, the laboratory cutoff concentrations for initial and confirmatory tests, and the chain of custody and reporting procedures, found in Part 40 Subpart F. The same regulation establishes the role of the medical review officer in Part 40 Subpart G, available at eCFR. The MRO is a licensed physician trained in controlled substances testing whose job is to review every confirmed positive result, contact the employee, and determine whether a legitimate medical explanation, such as a valid prescription, accounts for the result before it is reported to the employer. Non-DOT employers generally are not required by federal law to follow Part 40, but many adopt similar cutoff concentrations and MRO review as a matter of program design, and the full regulation is published at eCFR Title 49 Part 40.
Whether a program is DOT regulated or not, the practical path for an employee taking diclofenac is the same. Disclose current prescriptions and over the counter medications to the MRO when asked, keep the prescription label or pharmacy documentation available, and let the review process run its course rather than trying to explain a result at the collection site. The MRO, not the collector and not the employer, makes the final call on a confirmed positive.
For employers designing or updating a testing program, the practical takeaway is to build the review step into the process rather than relying on the screen alone. A positive point of care result should route automatically to confirmation testing and MRO review before any employment decision is made, and the program should give employees a clear channel to disclose current prescriptions before or at the time of collection. This is standard practice in DOT regulated programs and is widely adopted in non-regulated programs as well, since it protects both the integrity of the test result and the rights of an employee taking a legitimate medication such as diclofenac.
Frequently asked questions
Does diclofenac show up as THC on a drug test?
There is limited published evidence that diclofenac itself cross reacts with cannabinoid immunoassay screens. Older literature has flagged some other NSAIDs for occasional cross reactivity on certain assay formulations, but diclofenac is not well documented as a common cause, and any nonnegative screen is resolved through laboratory confirmation.
Can diclofenac cause a false positive for barbiturates?
A false positive barbiturate screen from diclofenac has not been well established in published literature. Reports describing NSAID related cross reactivity with barbiturate immunoassays generally point to other agents and older assay chemistries, and GC/MS or LC/MS confirmation testing reliably distinguishes diclofenac from an actual barbiturate metabolite.
Will a confirmation test clear up a false positive from diclofenac?
Yes. Confirmation testing by GC/MS or LC/MS identifies the specific molecule present, so it does not mistake diclofenac, or its metabolites, for THC or a barbiturate. Confirmation is the standard next step whenever a screening immunoassay returns a nonnegative result.
Does the topical diclofenac gel carry a different risk than the oral tablet?
Topical diclofenac gel has lower systemic absorption than the oral tablet or capsule, according to its DailyMed labeling. Neither form has a well documented connection to cannabinoid or barbiturate immunoassay cross reactivity, but mentioning which form was used helps the MRO evaluate any medication related question.
What should an employee do if a screen comes back nonnegative while taking diclofenac?
Report the prescription or over the counter use to the medical review officer when contacted, provide documentation such as a pharmacy label, and let the confirmation test and MRO review determine the outcome. Do not attempt to explain or dispute a result directly with the sample collector.
Is a drug test cup or dip card able to tell diclofenac apart from THC or barbiturates on its own?
A point of care immunoassay screen is not designed to identify a specific drug with certainty, only to flag whether a sample is negative or nonnegative for a drug class. Laboratory confirmation testing is what actually distinguishes diclofenac from THC or a barbiturate at the molecular level.
Related reading
- Does Naproxen Cause a False Positive Drug Test? NSAIDs, THC and Barbiturate Screens
- Does Meloxicam Show Up on a Drug Test? NSAIDs, THC Screens and Confirmation
American Screening Corporation supplies drug test cups, dip cards, oral fluid tests, and laboratory confirmation services for employers building or maintaining a workplace testing program. Browse the drug test cup collection to compare panel configurations.
This article is general information about drug testing science and procedure, not medical or legal advice. Employers and employees with specific medication or compliance questions should consult a medical review officer, a qualified physician, or legal counsel.